In 2014, we expanded our research activities in the immuno-oncology area by employing antibody generation technology against a number of targets believed to be important to the immune system's role in the establishment and progression of cancers. We have focused our internal activities in this area by creating mixtures of antibodies against multiple immuno-oncology targets with the goal of obtaining signals of activities initially in patients who did not benefit from single-target therapy.